Reimbursement “Furies” Real, But Won’t Avenge Pharma Til 2017, Says Citi

Posted on Dec 4, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Diagnostics, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing

“Beware the Three Furies,” warns Citi analyst Andrew Baum.  In a report for pharma investors published Nov. 29., Baum turns to classical mythology to describe shared savings models, drug pathways...

Learn More